Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with HCC who received curative liver resection (R0)and with positive expression of HAb18G/CD147 in the HCC tissues~2. Karnofsky Performance Score performance over 60~3. The functions of the kidney, heart and lung and the blood system are normal and fittable for Licardin therapy.~4. The liver function is of grade A or B in Child-Pugh classification.~5. Patients give consent to the test.~Exclusion Criteria:~1. Negative expression of HAb18G/CD147 in the HCC tissues~2. Allergic history to biologic products(Licartin)~3. Any of the situation list below: WBC less than 2000/ml, Hb less than 90g/L or PLT less than 50000/ml, bilirubin level more than 2.5 times the upper limit of normal value, serum albumin less than 32 g/l.~4. Severed disease of the heart, lung, kidney, brain and blood system.~5. Other severed disease might affect the trial .~6. Patients would not sign the consent to the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Licartin (Type: EXPERIMENTAL): patients who receive Licartin therapy after liver resection
- placebo (Type: NO_INTERVENTION): control group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group with patients who receive Licartin therapy after liver resection

Based on this trial design, predict the completion outcome and termination type (if applicable).